Results 211 to 220 of about 4,730,461 (228)

Cognitive functions and disability progression in relapsing-remitting multiple sclerosis: A longitudinal study

Applied Neuropsychology Adult, 2021
Anat Achiron, Eyal Heled, Roy Aloni
exaly  

Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis

Journal of Central Nervous System Disease, 2021
Yang Mao-Draayer, Jennifer Yang, Qin Wang   +2 more
exaly  

The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades

Multiple Sclerosis and Related Disorders, 2022
Cristina Masuet-aumatell, Lucía Romero Pinel, Isabel Leon   +2 more
exaly  

Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis

JAMA - Journal of the American Medical Association, 2012
Yinshan Zhao, Helen Tremlett, Mohammad Ehsanul Karim   +2 more
exaly  

Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis

Multiple Sclerosis Journal, 2008
Arthur F. Kramer, Robert Motl
exaly  

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study

Therapeutic Advances in Neurological Disorders, 2018
Gavin Giovannoni, Per Soelberg Sørensen, Giancarlo Comi   +2 more
exaly  

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Multiple Sclerosis Journal, 2018
Gavin Giovannoni, Per Soelberg Sørensen, Giancarlo Comi   +2 more
exaly  

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

Multiple Sclerosis Journal, 2012
Klaus Schmierer, Eva Havrdová, Ludwig Kappos   +2 more
exaly  

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

Lancet, The, 1998
George C. Ebers
exaly  

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Multiple Sclerosis Journal, 2020
Catherine Taylor, Annette Wundes, Tjalf Ziemssen   +2 more
exaly